To the Editor:We read with interest the recent publication by Dietz et al. 1 and would like to present additional data regarding salvage HCV treatment in this difficult-to-cure patient population.
Recently, we read with interest the publication by Berkan-Kawinska et al which compared real-world hepatitis C virus (HCV) treatment in patients with decompensated cirrhosis and compensated cirrhosis.Authors noted that use of treatment regimens including a protease inhibitor did not increase the risk of hepatic decompensation. 1 We would like to present additional data regarding the use of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy in this difficult-tocure patient population.Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.